Squarepoint
SGP

Squarepoint’s SpyGlass Pharma SGP Stock Holding History

Squarepoint’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$202K Buy
+7,811
New +$210K ﹤0.01% 3954

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Squarepoint's SGP Position: Q1 2026 in Review

Squarepoint opened a new position in SpyGlass Pharma (SGP) in Q1 2026: 7,811 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #3954 among its holdings.

35 funds tracked by Wall St. Rank hold SGP as of Q1 2026.

  • Squarepoint held 7,811 shares of SpyGlass Pharma worth $202K as of Q1 2026.
  • SpyGlass Pharma was a new Squarepoint position in Q1 2026.
  • SpyGlass Pharma made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3954 holding.
  • 35 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.